ReproNovo Raises $65 Million for Phase 2 Trials in Reproductive Medicine

ReproNovo, a biopharmaceutical company innovating in reproductive medicine and women's health, has successfully closed a $65 million Series A financing round. The financing was led by Jeito Capital, with co-leads AXA IM Alts and M Ventures, as well as syndicate support from Ysios Capital and ALSA Ventures. The funds will progress ReproNovo's Phase 2 clinical programs aimed at addressing male and female infertility and uterine health, notably through RPN-001, an oral treatment for male infertility due to low testosterone, and RPN-002, targeting adenomyosis and assisted reproductive success. ReproNovo's leadership includes seasoned specialists who have previously achieved clinical and commercial successes. Headquartered in Lausanne, Switzerland, ReproNovo operates with its main team in Copenhagen, Denmark, with an additional site in Barcelona, Spain. The investment supports the development of therapies that address significant public health concerns, with partners confident in ReproNovo's potential to redefine treatment landscapes.